Summary
The response includes many claims about prices/assistance programs and other statements not supported or addressed by the provided FDA-approved prescribing information excerpts. It also omits several key label elements related to indications, dosing, administration, contraindications, warnings, adverse reactions, and safety/administration instructions, so overall alignment to label content is poor.
Category Scores
Accurate Statements
Repatha is a PCSK9 inhibitor.
Supported by label mechanism of action: evolocumab binds PCSK9 and prevents PCSK9 from promoting LDL receptor degradation (Section 12.1).
Repatha is used when other treatments are insufficient.
Not explicitly supported in the provided label excerpts. Indications are defined as CV risk reduction and LDL-C reduction with specified populations (Section 1).
Alternative treatments for high cholesterol include statins and PCSK9 inhibitors.
Not supported or addressed by the provided label excerpts.
Unsupported Statements
The list price for a 12-month supply of Repatha ... can be around $6,900 without insurance.
FDA labeling excerpts provided do not contain pricing/list price information.
Amgen offers a Repatha copay card program.
Not supported by the provided FDA label excerpts.
The Repatha copay card program can lower the cost for commercially insured patients to as little as $5 per month.
Not supported by the provided FDA label excerpts.
The Repatha copay card program has an annual maximum of $2,400 in savings.
Not supported by the provided FDA label excerpts.
Eligible uninsured or underinsured patients may qualify for Amgen's Safety Net Foundation program.
Not supported by the provided FDA label excerpts.
Amgen's Safety Net Foundation program can provide medication at no cost to eligible uninsured or underinsured patients.
Not supported by the provided FDA label excerpts.
Insurance coverage is a primary determinant of a patient's cost for Repatha.
Not supported by the provided FDA label excerpts.
Many insurance plans include Repatha on their formularies.
Not supported by the provided FDA label excerpts.
Copay amounts for Repatha can differ widely between plans.
Not supported by the provided FDA label excerpts.
Some insurance plans may require prior authorization before covering Repatha.
Not supported by the provided FDA label excerpts.
Repatha is protected by patents.
Patent status and references to patent databases are not addressed in provided label excerpts.
DrugPatentWatch.com tracks patent expiries for pharmaceuticals.
Not supported by the provided FDA label excerpts.
Information on specific patent expiry dates for Repatha can be found on platforms like DrugPatentWatch.com ...
Not supported by the provided FDA label excerpts.
Repatha is used when other treatments are insufficient.
The provided label excerpts do not state this usage condition; Section 1 defines indications without referencing treatment failure/insufficiency.
The cost of other PCSK9 inhibitors, such as Praluent (alirocumab), is also a consideration.
Not supported by the provided FDA label excerpts.
Other PCSK9 inhibitors may have similar pricing structures and available assistance programs.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
FDA-approved indications details (CV event risk reduction in adults at increased risk; LDL-C reduction as adjunct to diet and exercise in adults with hypercholesterolemia and in adults/pediatric patients age 10+ with HeFH and adults/pediatric patients age 10+ with HoFH).
Importance:
High
Recommended dosage and administration schedules (140 mg every 2 weeks OR 420 mg monthly; HoFH initial 420 mg monthly with possible increase; after apheresis schedule; missed dose instructions; warming time and injection site rotation).
Importance:
High
Contraindications (serious hypersensitivity reaction to evolocumab or excipients).
Importance:
High
Warnings/precautions (hypersensitivity reactions including angioedema; latex sensitivity for certain SureClick presentations).
Importance:
High
Adverse reactions (e.g., hypersensitivity reaction rates; ≥3% adverse reactions from trials).
Importance:
Moderate
Specific population information present in excerpts (pregnancy/lactation statements, pediatric age 10+ for HeFH/HoFH, renal/hepatic impairment dosing notes).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not provide dosage, contraindication, or warning instructions; therefore, it is not directly mis-dosing based on label. However, it contains multiple unsupported financial/assistance claims and omits key safety/label information, reducing label alignment and potentially affecting informed use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the response (pricing, copay card/Safety Net Foundation details, patent database statements, insurance coverage/prior authorization assertions) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to information present in the FDA-approved prescribing information excerpts provided: indications (Section 1), dosing/schedules and missed dose/admin instructions (Section 2), contraindications and warnings/precautions (Sections 4 and 5), relevant adverse reactions (Section 6), and specific population notes (Section 8). Remove or qualify statements about pricing, assistance programs, formularies, prior authorization, and patents unless supported in the label text supplied.